For lung cancer, Wang et al. [39] reported that FOXM1 expression could predict the outcome and sensitivity to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Here, FOXM1 is linked to non-small cell lung carcinoma.